Table 1.

Linear regression model.

	PLB		SERCA		PLB/SERCA		PKP		Plako		ZASP
	β	p	β	p	β	p	β	p	β	p	β	P
Age	0.07	0.36	−0.1	0.34	0.04	0.66	−0	0.97	0.1	0.41	0.1	0.48
EF	0.05	0.52	−0.1	0.12	−0	0.87	−0	0.93	−0.1	0.39	−0	0.75
Statins	−0	0.8	0.05	0.52	0.11	0.28	0	1	0.08	0.541	−0.2	0.18
CCS	−0.1	0.46	0.02	0.84	−0.1	0.21	−0.2	0.2	0.05	0.705	0.23	0.12
ASS	−0.2	0.04	0.03	0.74	0.11	0.34	0.05	0.81	−0.4	0.002	0.01	0.95
ACE or AT1	0.1	0.25	−0	0.9	−0	0.72	0.04	0.83	0.3	0.017	−0.1	0.4
PLB			0.78	0	0.79	0	0.04	0.91	−0.3	0.209	−0.2	0.54
SERCA	0.81	0			−0.9	0	−0.1	0.7	−0.1	0.728	0.17	0.52
PLB/SERCA	0.51	0	−0.6	0			−0.3	0.29	−0	0.954	0.04	0.84
PKP	0.01	0.91	−0	0.7	−0.1	0.29			0.01	0.962	0.14	0.29
Plako	−0.1	0.21	−0	0.73	−0	0.95	0.01	0.96			0.34	0.04
ZASP	−0.1	0.54	0.06	0.52	0.02	0.84	0.2	0.29	0.28	0.043

Protein expression data were normalized to CSQ expression.

β, standardized regression coefficient; ACE, Angiotensin-converting enzyme antagonist; ASS, acetylsalicylic acid; AT1, angiotensin receptor type 1 antagonist; CCS, Canadian Cardiovascular Society angina class; EF, ejection fraction; PKP, plakophilin; Plako, plakoglobin; PLB, phospholamban; SERCA, sarcoplasmic reticulum Ca²⁺-ATPase; ZASP, Cypher/ZASP.